drugset / Trial / NCT00631410

Study Of Sunitinib In Combination With Folfox In Patients With Colorectal Cancer

NCT00631410

Phase 1 Completed 12 enrolled Pfizer
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To assess the safety and tolerability of sunitinib when administered in combination with modified FOLFOX6 in Japanese patients with metastatic colorectal cancer in the first-line treatment setting.

Timeline

Start
2008-01
Primary completion
2009-07
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Sunitinib Small molecule 37.5 mg Oral
Subject Sunitinib Small molecule 50 mg Oral
Background Levoleucovorin Unknown
Background Oxaliplatin Small molecule
Background fluorouracil Small molecule

Indications